Author:
James Nicole E.,Woodman Morgan,DiSilvestro Paul A.,Ribeiro Jennifer R.
Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have heavily focused on immunotherapeutic approaches, centered upon programmed cell death 1 (PD-1) inhibitors. While PD-1 monotherapies have only exhibited modest responses for patients, it has been theorized that in order to enhance EOC patient response to immunotherapy, combinatorial regimens must be investigated. In this review, unique challenges to EOC PD-1 response will be discussed, along with a comprehensive description of both preclinical and clinical studies evaluating PD-1-based combinatorial therapies. Promising aspects of PD-1-based combinatorial approaches are highlighted, while also discussing specific preclinical and clinical areas of research that need to be addressed, in order to optimize EOC patient immunotherapy response.
Reference136 articles.
1. Cancer Statistics Center—Ovaryhttps://cancerstatisticscenter.cancer.org/#!/cancer-site/Ovary
2. Treatment of recurrent ovarian cancer
3. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
4. Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis
5. Niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer [published online ahead of print, 2020 Mar 16];Kerliu;Ann. Pharmacother.,2020
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献